Physician profile
Kenton E Forte
NPI 1326023953
$144,404.94
in general payments reported to CMS, 2019-2025
18 companies · $599 in 2025
The $599 reported for 2025 was more than what 86% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96K · 2020: $34K · 2021: $4,185 · 2022: $8,123 · 2023: $973 · 2024: $412 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $103,685.48 | 2019-2021 | |
| Amgen INC. | $35,636.41 | 2019-2023 | Repatha |
| Romark Laboratories, Lc | $3,000.00 | 2019 | |
| Kestra Medical Technology Services, INC. | $938.75 | 2022-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $262.92 | 2019-2020 | |
| Boston Scientific Corporation | $258.64 | 2023-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Impulse Dynamics (USA) INC. | $139.22 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $115.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.05 | 2019-2024 | Jardiance |
| Pfizer INC. | $69.19 | 2019-2020 | |
| Biotronik INC. | $47.56 | 2019-2020 | |
| Abbott Laboratories | $33.64 | 2024 | Aveir |
| Arbor Pharmaceuticals, INC. | $29.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.79 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.09 | 2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $16.96 | 2025 | Camzyos |
| Novo Nordisk INC | $15.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,151,183.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenton Forte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.